SCHEMBL6765894

SCHEMBL6765894

CCOC(=O)c1cc(C)nn1-c1ccc2cc(OC)ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
HTT P42858 2/20 0.54
KMT2A Q03164 2/20 0.54
USP2 O75604 1/20 0.54
PDE4D Q08499 1/20 0.53
F10 P00742 1/20 0.49
FAAH O00519 2/20 0.48
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 4/20 0.48
HPGD P15428 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
NPC1 O15118 2/20 0.46
LMNA P02545 2/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
POLB P06746 2/20 0.46
APEX1 P27695 1/20 0.46
RECQL P46063 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1873573 0.90 PDE4D (0.61) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL6764400 0.88 KDM4E (0.57) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL6763701 0.86 SMN1; SMN2 (0.50) SMN1; SMN2HTTKMT2AUSP2F10
SCHEMBL6761508 0.85 SMN1; SMN2 (0.49) SMN1; SMN2HTTKMT2AUSP2F10
SCHEMBL6769718 0.81 PDE4D (0.53) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL1877271 0.79 SMN1; SMN2 (0.52) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL7229599 0.79 POLB (0.62) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL7233562 0.79 SMN1; SMN2 (0.50) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL14217732 0.78 PDE4D (0.60) SMN1; SMN2HTTKMT2AUSP2PDE4D
SCHEMBL5344577 0.78 MAPT (0.53) SMN1; SMN2KMT2AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116399-A1 Inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2004-06-17 US disclosed
US-6720317-B1 1-NAPHTH-2-YL-1H-PYRAZOLE-5-(4-AMIDINOPHENYL)CARBOXYAMIDE, MULTIPLY SUBSTITUTED; NON AMIDINO ANTICOAGULANTS; HEMOSTATIC AGENTS MILLENNIUM PHARMACEUTICALS, INC. 2004-04-13 US disclosed
US-6686368-B1 Inhibitors of factor Xa MILLENNIUM PAHRMACEUTICALS, INC. 2004-02-03 US disclosed
US-6632815-B2 Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades MILLENNIUM PHARMACEUTICALS, INC. 2003-10-14 US disclosed
US-20020091116-A1 Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades MILLENNIUM PHARMACEUTICALS, INC. 2002-07-11 US disclosed
EP-1216231-A2 INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2002-06-26 EP disclosed
WO-2001019798-A2 INHIBITORS OF FACTOR Xa COR THERAPEUTICS INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091116-A1 Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades SERPINC1, TFPI, F2 SMN1; SMN2 3156/4885HTT 4129/4885KMT2A 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.